Stockscreener 앱 받기
2.55
8.05%
0.19
시간 외 거래:
2.50
-0.05
-1.96%
전일 마감가:
$2.36
열려 있는:
$2.36
하루 거래량:
3.22M
Relative Volume:
1.20
시가총액:
$863.62M
수익:
$796.85M
순이익/손실:
$30.44M
주가수익비율:
30.29
EPS:
0.0842
순현금흐름:
$93.88M
1주 성능:
+10.39%
1개월 성능:
+26.87%
6개월 성능:
-24.33%
1년 성능:
-45.04%
1일 변동 폭
$2.355
$2.60
1주일 범위
$2.255
$2.60
52주 변동 폭
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, DOCS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.55 | 863.62M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
171.60 | 28.03B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
52.58 | 10.16B | 12.91B | 104.80M | 394.69M | 0.8769 |
TEM
Tempus Ai Inc
|
55.00 | 9.87B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.40 | 6.96B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
24.98 | 4.61B | 637.78M | 239.40M | 307.21M | 1.1909 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
GoodRx (NASDAQ: GDRX) CAO Thomas Chan reports stock, options and RSUs - Stock Titan
GoodRx offers oral semaglutide starting at $149 per month By Investing.com - Investing.com India
GoodRx expands offerings to now include Ozempic® pill for type 2 diabetes patients - marketscreener.com
GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients - Quantisnow
A new Ozempic pill now starts at $149 a month through GoodRx - Stock Titan
[ARS] GoodRx Holdings, Inc. SEC Filing - Stock Titan
Executive pay, auditor change headline GoodRx (NASDAQ: GDRX) 2026 vote - Stock Titan
What's Going On With GoodRx Stock Thursday? - Sahm
GDRX vs. HQY: Which Stock Is the Better Value Option? - MSN
GoodRx (GDRX) Q2 2024 earnings summary - Quartr
GoodRx won't be participating with TrumpRx: report - MSN
What's going on with GoodRx stock Thursday? - MSN
GoodRx Holdings, Inc. Appoints New Chief Accounting Officer and Files Form 8-K with SEC - Minichart
GoodRx appoints Thomas Chan as chief accounting officer By Investing.com - Investing.com India
GoodRx Names Thomas Chan Chief Accounting Officer - TipRanks
GoodRx appoints Thomas Chan as chief accounting officer - Investing.com
GoodRx names Thomas Chan as Chief Accounting Officer - TradingView
GoodRx (NASDAQ: GDRX) appoints Thomas Chan as new Chief Accounting Officer - Stock Titan
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy? - The Globe and Mail
GDRX GoodRx Holdings shares climb 4.41 percent after Q4 2025 results despite a minor EPS miss against analyst expectations.Social Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GDRX (GoodRx Holdings Inc.) drops 3.4% today after Q4 2025 EPS narrowly falls short of analyst expectations.Risk Event - Xã Thanh Hà
GoodRx Holdings (GDRX) Sector Leadership | Q4 2025: EPS Misses EstimatesSector Outperform - Cổng thông tin điện tử tỉnh Tây Ninh
Healthcare Technology Stocks Q4 Recap: Benchmarking GoodRx (NASDAQ:GDRX) - Barchart.com
GoodRx Holdings (GDRX) Stock Municipal Bond (Slight Rise) 2026-04-20Crowd Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GoodRx Holdings (GDRX) Stock Trade Ticket (-3.40%) 2026-04-18Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call - 01net
GoodRx rallies as Wegovy HD rollout targets self-pay market - MSN
GDRX Forecast, Price Target & Analyst Ratings | GOODRX HOLDINGS INC-CLASS A (NASDAQ:GDRX) - ChartMill
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market - Sahm
3 Reasons GDRX is Risky and 1 Stock to Buy Instead - The Globe and Mail
Why GoodRx (GDRX) Stock Is Up Today - Yahoo Finance
[Form 4] GoodRx Holdings, Inc. Insider Trading Activity - Stock Titan
GoodRx (GDRX) director Wendy Lynn Barnes converts RSUs and uses 120,456 shares for taxes - Stock Titan
A higher-dose Wegovy now costs $399 a month through GoodRx - Stock Titan
GoodRx Holdings (GDRX) price target decreased by 38.27% to 2.87 - MSN
Gains Report: What is the next catalyst for GoodRx Holdings IncWeekly Trade Recap & High Accuracy Swing Trade Signals - baoquankhu1.vn
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Nasdaq Moves: How does GoodRx Holdings Inc perform in inflationary periods2026 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
GDRX News | GOODRX HOLDINGS INC-CLASS A (NASDAQ:GDRX) - ChartMill
GoodRx brings Lilly's new weight-loss pill to pharmacies nationwide - Stock Titan
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Goodrx Holdings Inc 주식 (GDRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
1.72%
1.86%
자본화:
|
볼륨(24시간):